Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist

• Published in: European journal of pharmacology Vol. 592; no. 1; pp. 158 - 159
• Main Authors: Gardell, Luis R., Hyldtoft, Lene, Del Tredici, Andria L., Andersen, Carsten B., Fairbairn, Luke C., Lund, Birgitte W., Gustafsson, Magnus, Brann, Mark R., Olsson, Roger, Piu, Fabrice
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 11.09.2008; Elsevier
• Subjects: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological and medical sciences; Carrageenan; Chronic Disease; Estrogen receptor beta; Estrogen Receptor beta - agonists; Formaldehyde; Freund's Adjuvant; Hyperalgesia - chemically induced; Hyperalgesia - drug therapy; Inflammation; Inflammation - chemically induced; Inflammation - drug therapy; Inflammation - etiology; Male; Medical sciences; Pain; Pain - chemically induced; Pain - drug therapy; Pain - etiology; Pain Measurement - drug effects; Pharmacology. Drug treatments; Rats; Rats, Sprague-Dawley; Estrogen receptor beta; Inflammation; Pain; Estrogen receptor β; Agonist
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2008.06.107

To understand the contribution of the estrogen receptor beta, the potent and selective agonist ERb-131 was evaluated in animal models of inflammatory pain. In paradigms of acute and persistent inflammatory pain, ERb-131 did not alleviate the nociception induced by either carrageenan or formalin. However, in the chronic complete Freund's adjuvant model, ERb-131 resolved both inflammatory and hyperalgesic components. Thus, ERb-131 is sufficient to alleviate chronic but not acute inflammatory pain states.